Telephone
61.2.9144.2223
Address
Level 20 Tower A, The Zenith 821 Pacific Highway Chatswood, New South Wales (NSW) 2067
Description
Noxopharm Ltd. engages in the research and development of drugs. It focuses on sensitizing cancer cells to radiotherapy and chemotherapy. The company was founded by Graham Kelly on October 27, 2015 and is headquartered in Gordon, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.17
Trade Value (12mth)
AU$11,430.00
1 week
-9.09%
1 month
-9.09%
YTD
-31.03%
1 year
-37.5%
All time high
1.58961
EPS 3 yr Growth
2475.000%
EBITDA Margin
N/A
Operating Cashflow
-$11m
Free Cash Flow Return
-66.00%
ROIC
-90.70%
Interest Coverage
-401.00
Quick Ratio
9.50
Shares on Issue (Fully Dilluted)
292m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.13
Date | Announcements |
---|---|
31 March 20 |
Noxopharm Virtual Roadshow Corporate Presentation
×
Noxopharm Virtual Roadshow Corporate Presentation |
31 August 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 August 23 |
Appendix 4E and Audited Financial Statements
×
Appendix 4E and Audited Financial Statements |
29 March 21 |
Corporate Presentation for Switzer Virtual Investor Day
×
Corporate Presentation for Switzer Virtual Investor Day |
29 March 21 |
Noxopharm Ltd. - Corporate Presentation for Switzer Virtual Investor Day (NOX-AU)
×
Noxopharm Ltd. - Corporate Presentation for Switzer Virtual Investor Day (NOX-AU) |
29 June 23 |
Change of Director's Interest Notice - FB
×
Change of Director's Interest Notice - FB |
29 January 20 |
Noxopharm Non-Deal Roadshow Presentation
×
Noxopharm Non-Deal Roadshow Presentation |
28 September 23 |
2023 AGM Letter to Shareholders and Proxy
×
2023 AGM Letter to Shareholders and Proxy |
28 September 23 |
2023 AGM Notice of Meeting and Proxy
×
2023 AGM Notice of Meeting and Proxy |
28 September 23 |
Latest CRO-67 data shows success in reducing cancer growth
×
Latest CRO-67 data shows success in reducing cancer growth |
28 March 23 |
Noxopharm Announces Novel mRNA Vaccine Enhancer
×
Noxopharm Announces Novel mRNA Vaccine Enhancer |
28 June 21 |
Noxopharm Corporate Presentation
×
Noxopharm Corporate Presentation |
28 June 21 |
Noxopharm Ltd. - Noxopharm Corporate Presentation (NOX-AU)
×
Noxopharm Ltd. - Noxopharm Corporate Presentation (NOX-AU) |
28 January 21 |
Noxopharm To Present to ShareCafe Hidden Gems Webinar
×
Noxopharm To Present to ShareCafe Hidden Gems Webinar |
28 January 21 |
Noxopharm Ltd. - Noxopharm To Present to ShareCafe Hidden Gems Webinar (NOX-AU)
×
Noxopharm Ltd. - Noxopharm To Present to ShareCafe Hidden Gems Webinar (NOX-AU) |
28 February 22 |
First Patient Treated in CEP-2 Sarcoma Trial
×
First Patient Treated in CEP-2 Sarcoma Trial |
28 February 22 |
Noxopharm Ltd. - First Patient Treated in CEP-2 Sarcoma Trial (NOX-AU)
×
Noxopharm Ltd. - First Patient Treated in CEP-2 Sarcoma Trial (NOX-AU) |
28 April 22 |
March 2022 Quarterly Activities Report and Appendix 4C
×
March 2022 Quarterly Activities Report and Appendix 4C |
27 September 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 September 18 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 October 23 |
Unlisted Options Expiring on 16 December 2023
×
Unlisted Options Expiring on 16 December 2023 |
27 November 17 |
AGM Presentations
×
AGM Presentations |
27 May 22 |
Veyonda Abstract Published at ASCO Annual Meeting 2022
×
Veyonda Abstract Published at ASCO Annual Meeting 2022 |
27 July 22 |
June 2022 Quarterly Activities Report and Appendix 4C
×
June 2022 Quarterly Activities Report and Appendix 4C |
27 January 23 |
December 2022 Quarterly Activities Report and Appendix 4C
×
December 2022 Quarterly Activities Report and Appendix 4C |
27 January 22 |
December 2021 Quarterly Activities Report and Appendix 4C
×
December 2021 Quarterly Activities Report and Appendix 4C |
27 January 22 |
Noxopharm Ltd. - December 2021 Quarterly Activities Report and Appendix 4C (NOX-AU)
×
Noxopharm Ltd. - December 2021 Quarterly Activities Report and Appendix 4C (NOX-AU) |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.